CN111995675A - Monoclonal antibody aiming at new coronavirus SARS-CoV-2 spinous process protein RBD region and application thereof - Google Patents

Monoclonal antibody aiming at new coronavirus SARS-CoV-2 spinous process protein RBD region and application thereof Download PDF

Info

Publication number
CN111995675A
CN111995675A CN202010922039.4A CN202010922039A CN111995675A CN 111995675 A CN111995675 A CN 111995675A CN 202010922039 A CN202010922039 A CN 202010922039A CN 111995675 A CN111995675 A CN 111995675A
Authority
CN
China
Prior art keywords
cov
monoclonal antibody
sars
seq
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202010922039.4A
Other languages
Chinese (zh)
Other versions
CN111995675B (en
Inventor
董金华
李海梅
陈丽梅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Weifang Medical University
Original Assignee
Weifang Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Weifang Medical University filed Critical Weifang Medical University
Publication of CN111995675A publication Critical patent/CN111995675A/en
Application granted granted Critical
Publication of CN111995675B publication Critical patent/CN111995675B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35Valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/165Coronaviridae, e.g. avian infectious bronchitis virus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00Immunoassays for the detection of microorganisms
    • G01N2469/10Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)

Abstract

The invention discloses a monoclonal antibody against new coronavirus SARS-CoV-2 spinous process protein RBD region and its application, the monoclonal antibody is specifically combined with new coronavirus SARS-CoV-2 spinous process glycoprotein RBD region, including complementarity determining regions CDRH1, CDRH2, CDRH3 of heavy chain variable region and complementarity determining regions CDRL1, CDRL2, CDRL3 of light chain variable region; the monoclonal antibody aiming at the spinous process protein RBD region of the SARS-CoV-2 of the new coronavirus has high titer and strong specificity, can be efficiently expressed, can be specifically combined with the spinous process protein RBD region on the surface of the SARS-CoV-2 of the new coronavirus, can be used for detecting the SARS-CoV-2 of the new coronavirus, neutralizes and weakens certain toxicity of the new coronavirus, and plays a role in preventing or/and treating pneumonia of the new coronavirus.

Description

Monoclonal antibody aiming at new coronavirus SARS-CoV-2 spinous process protein RBD region and application thereof
Technical Field
The invention relates to the technical field of biotechnology, in particular to cellular immunology and molecular biology technologies, and specifically relates to a monoclonal antibody aiming at a novel coronavirus SARS-CoV-2 spinous process protein RBD region and application thereof.
Background
The novel coronavirus SARS-CoV-2 is a single-stranded positive-strand RNA virus whose genome encodes 4 structural proteins: spinous process protein (S), small protein (E), matrix protein (M), and nucleocapsid protein (N). The S protein is a type I fusion protein, forms a trimer on the surface of virus particles, and consists of two subunits, namely S1 subunit and S2 subunit: s1 is responsible for receptor binding and S2 is responsible for membrane fusion. The Receptor Binding Domain (RBD) in S1 interacts with the human SARS-CoV receptor angiotensin converting enzyme II (ACE2) molecule, while S2 contains essential elements required for the membrane fusion process to achieve fusion of virus and cell, i.e., SARS-CoV-2 uses angiotensin converting enzyme 2(ACE2) as a receptor to enter target cells, and thus, the S protein determines the infectivity and its transmissibility in the host. And because the S protein is a main antigen for inducing protective immune response, the research and development of the vaccine mainly take the S protein as a target. It is therefore crucial to closely monitor the antigenic changes in the S protein of the spreading new coronavirus SARS-CoV-2.
Antibodies are important glycoprotein molecules in the mammalian immune system. The molecular structure is composed of two Heavy chains (Heavy chain) and two Light chains (Light chain), wherein the Heavy chain is divided into a Variable region of the Heavy chain (VH) and three Constant regions (Constant region of the Heavy chain; CH1, CH2, CH3), and the Light chain is composed of a Variable region (VL) and a Constant region (CL). The variable region has a function of specifically binding to an antigen, and is different from individual antibody, while the constant region of an antibody is determined by the species and subtype of the antibody. The heavy chain variable region of an antibody comprises three Complementarity determining regions (CDRH 1, CDRH2, CDRH3) and the light chain variable region also comprises three Complementarity determining regions (CDRL 1, CDRL2, and CDRL 3), which are also known as hypervariable regions and directly bind to an epitope.
At present, no specific therapeutic drug or vaccine aiming at the new coronavirus is available on the market, and the anti-new coronavirus drugs mainly comprise small-molecule drugs of Reiciclovir, chloroquine and hydroxychloroquine, lopinavir and ritonavir and three drugs of lopinavir, ritonavir and interferon, but have no obvious therapeutic effect and some even serious toxic and side effects. On the other hand, antibody drugs play an important role in the treatment of infectious diseases, autoimmune diseases, tumors and the like, and the development of monoclonal antibodies against the novel coronavirus SARS-CoV-2 is of great practical significance under the conditions that the SARS-CoV-2 vaccine which is currently faced is difficult to develop and has a long period and the great side effect of the traditional drugs is not obvious.
Disclosure of Invention
In order to solve the problems, the invention aims to provide a monoclonal antibody aiming at the RBD region of the spike protein of the novel coronavirus SARS-CoV-2 and application thereof.
In order to achieve the purpose, the invention is realized by the following technical scheme:
the invention discloses a monoclonal antibody aiming at a new coronavirus SARS-CoV-2 spinous process protein RBD region, which is specifically combined with the new coronavirus SARS-CoV-2 spinous process glycoprotein RBD region and comprises complementarity determining regions CDRH1, CDRH2, CDRH3 of a heavy chain variable region and complementarity determining regions CDRL1, CDRL2 and CDRL3 of a light chain variable region; the amino acid sequences of the complementarity determining regions CDRH1, CDRH2 and CDRH3 of the heavy chain variable region are SEQ ID NO: 2. SEQ ID NO: 3 and SEQ ID NO: 4; the amino acid sequences of the complementarity determining regions CDRL1, CDRL2 and CDRL3 of the light chain variable region are SEQ ID NO: 6. SEQ ID NO: 7 and SEQ ID NO: 8.
a preferred monoclonal antibody aiming at the RBD region of the spinous process protein of the novel coronavirus SARS-CoV-2 is named C3, and the amino acid sequence of the heavy chain variable region of the monoclonal antibody is SEQ ID NO: 1, the amino acid sequence of the light chain variable region of the monoclonal antibody is SEQ ID NO: 5.
the invention also includes an isolated nucleic acid molecule encoding a monoclonal antibody as described in any one of the above.
The invention also includes an expression vector comprising a nucleic acid molecule as described above, which expression vector comprises, in addition to the nucleic acid molecule as described above, an expression control sequence operably linked to the sequence of said nucleic acid molecule.
An expression vector refers to a nucleic acid vehicle into which a polynucleotide encoding the C3 antibody can be inserted and the C3 antibody expressed. The vector may be transformed, transduced or transfected into a host cell so that the genetic material elements it carries are expressed within the host cell. Types of vectors include bacterial plasmids, bacteriophages, yeast plasmids, plant cell viruses, mammalian cell viruses such as adenoviruses, retroviruses, or other vectors well known in the art. In principle, any vector may be used as long as it is replicable and stable in the host. In addition to the origin of replication, the expression vector may contain a marker gene and other translational regulatory elements.
The invention also includes a host cell comprising a nucleic acid molecule as described above or an expression vector as described above.
The host cell expressing the C3 antibody can be a prokaryotic cell, such as a bacterial cell; or lower eukaryotic cells, such as yeast cells; or higher eukaryotic cells, such as mammalian cells. Representative examples are: escherichia coli, Streptomyces; bacterial cells of salmonella typhimurium; fungal cells such as yeast; a plant cell; insect cells of Drosophila S2 or Sf 9; CHO, COS, 293 cells or Bowes melanoma cells.
The invention also includes a method for detecting the level of the novel coronavirus SARS-CoV-2 for non-diagnostic purposes, comprising the steps of:
extracting a sample containing new coronavirus SARS-CoV-2;
contacting the sample obtained in the step I with the monoclonal antibody C3;
and thirdly, detecting the immunoreaction of the sample and the monoclonal antibody.
The invention also includes the application of the monoclonal antibody aiming at the new coronavirus SARS-CoV-2 spinous process protein RBD zone in the preparation of new coronavirus SARS-CoV-2 detection products.
The detection product includes, but is not limited to, a detection reagent, a kit, a chip or a test paper. Any assay product capable of detecting SARS-CoV-2 comprising a binding molecule as described above is included within the scope of the invention.
The invention also includes the application of the monoclonal antibody aiming at the new coronavirus SARS-CoV-2 spinous process protein RBD region in the preparation of the medicine for inhibiting the new coronavirus SARS-CoV-2 antibody.
The invention also includes the application of the monoclonal antibody aiming at the spinous process protein RBD region of the new coronavirus SARS-CoV-2 in the preparation of an antibody pharmaceutical preparation for preventing or treating pneumonia caused by the new coronavirus SARS-CoV-2.
The terms "new coronavirus SARS-CoV-2" and "SARS-CoV-2 virus", "new coronavirus", "SARS-CoV-2" and "new coronavirus SARS-CoV-2" used in the present invention can be used interchangeably.
Compared with the prior art, the invention has the following advantages:
the monoclonal antibody aiming at the spinous process protein RBD region of the SARS-CoV-2 of the new coronavirus has high titer and strong specificity, can be efficiently expressed, can be specifically combined with the spinous process protein RBD region on the surface of the SARS-CoV-2 of the new coronavirus, can be used for detecting the SARS-CoV-2 of the new coronavirus, neutralizing and weakening certain toxicity of the new coronavirus, and plays a role in preventing or/and treating pneumonia of the new coronavirus.
The phage display technology inserts exogenous DNA into the gene of phage coding coat protein, so that the expression product corresponding to the exogenous DNA fragment is fused in the coat protein of the phage to form fusion protein, and the fusion protein is displayed on the surface of the phage. Has the following remarkable advantages: direct physical connection between the genotype and the phenotype is established, so that the screening is simple, convenient and efficient. The invention screens the antibody which can be combined with the S protein of the new coronavirus SARS-CoV-2 from the synthetic antibody library Tomlinson I + J phage display antibody library, and the antibodies have important application value in the aspects of detecting the new coronavirus and weakening the virus toxicity.
Drawings
FIG. 1 shows the results of enzyme-linked immunoassay for the antigen binding performance of phages obtained by panning an antibody library;
FIG. 2 shows the results of ELISA assay for the antigen specificity of monoclonal antibody C3;
FIG. 3 shows the results of ELISA assay for the antigen specificity of monoclonal antibody A3;
FIG. 4 is a schematic diagram showing the principle of detection of new coronavirus using panning antibodies C3 and A3;
FIG. 5 is the results of detection of viral S protein by the C3 antibody in combination with phage-displayed A3.
Detailed Description
The invention aims to provide a monoclonal antibody aiming at a new coronavirus SARS-CoV-2 spinous process protein RBD region and application thereof, which are realized by the following technical scheme:
the present invention aims at providing monoclonal antibody against new coronavirus SARS-CoV-2 spike protein RBD region and its application, and the present invention is further illustrated by the following examples. The examples of the invention are intended to be illustrative and not limiting, and simple modifications thereof in accordance with the principles of the invention are intended to be within the scope of the claims. The invention is further described with reference to specific examples.
Example 1
Amplification of a phage display antibody library:
mu.L of E.coli TG-1 (MRC HGMP resources center, UK) containing Tomlinson I + J phage display antibody library was inoculated into 25mL of 2YT medium (1.6% Tryptone, 1% Yeast Extract, 0.5% NaCl) containing 100. mu.g/mL ampicillin and 1% glucose, and cultured at 37 ℃ to OD600At 0.4, add 109cfu (Colony Formation Unit) KM13 helper phage (MRC HGMP resources center, UK), 1 hour after infection at 37 ℃, 3000g was centrifuged for 30 minutes, the supernatant was discarded, and ammonia containing 100. mu.g/ml was usedBenzyl penicillin, 50. mu.g/mL kanamycin and 0.1% glucose in 2YT medium 50mL (1.6% Tryptone, 1% Yeast Extract, 0.5% NaCl) suspension of the thalli, 30 ℃, 250rpm speed shake bacteria for 16 hours, the next day 5000g, 30 minutes centrifugal culture fluid, separation and recovery of supernatant 40mL, in the supernatant adding 10mL PEG/NaCl solution, mixing evenly, then on ice for 30 minutes, 5000g, 30 minutes centrifugal, discard the supernatant, adding 2mL sterile PBS solution to dissolve the precipitate, as phage display antibody library solution, using Escherichia coli to titrate the phage display antibody library, the concentration of the prepared antibody library is 1012cfu/mL。
Second, panning of phage display antibody library
mu.L of a PBS solution containing 10. mu.g/ml of SARS-CoV-2 virus S protein (Nanjing Kingkumquat Biotech Co., Ltd.) was added to each of 10 wells of a 96-well microplate, overnight incubation was performed at 4 ℃ and the antigen solution was discarded the next time, 200. mu.L of a PBS solution containing 2% skim milk powder was added to each well, incubation was performed at 25 ℃ for 2 hours for blocking, and after 3 times of PBST washing, 100. mu.L of a phage solution (R0; each well containing 10. mu.L of the antigen solution) was added to each well9cfu phage) were incubated at room temperature for 2 hours, and after washing with PBST, phage bound to viral S protein were eluted by adding 100 μ L trypsin per well.
Culturing TG-1 E.coli to OD600Taking 4mL of bacterial liquid, adding 500 mu L of dissolved phage solution into the bacterial liquid, infecting for 30 minutes at 37 ℃, centrifuging for 20 minutes at 5000g, discarding the supernatant, suspending the bacterial cells by using a 2YT culture medium containing 100 mu g/mL ampicillin, 50 mu g/mL kanamycin and 0.1% glucose, and shaking the bacterial cells for 16 hours at 30 ℃ and 250 rpm; centrifuging the culture solution for 30 minutes at 5000g the next day, separating and recovering the supernatant, adding 1/5 volumes of PEG/NaCl solution into the supernatant solution, uniformly mixing, placing on ice for 30 minutes, centrifuging for 30 minutes at 5000g, discarding the supernatant, and adding 200 μ L of sterilized PBS solution to serve as phage solution (R1) after the first enrichment; repeating the steps to respectively obtain phage solutions R2 and R3; and performing enzyme-linked immunosorbent assay, and verifying the binding specificity and binding performance of the phage display antibody library and the S protein obtained in the panning process.
Enzyme linked immunosorbent assayThe operation of the test is as follows: 100. mu.L of PBS containing a neocoronavirus S protein solution (2. mu.g/mL) or bovine serum albumin BSA (2. mu.g/mL) was added to a 96-well plate, overnight at 4 ℃, the antigen solution was discarded the next day, 200. mu.L of a solution containing 2% skim milk powder was added, and the plate was incubated at 25 ℃ for 2 hours and then blocked. The microplate was washed 3 times with PBS containing 0.1% Tween 20, and diluted R0, R2 and R3 phage solutions (10) were added9cfu/well), incubation at 25 ℃ for 1 hour, washing the microplate with PBST solution, addition of HRP-labeled mouse anti-M13 antibody, incubation for 1 hour, washing the plate with PBST, addition of HRP substrate TMBZ (prepared with sodium acetate solution pH6.0, containing 1/10000 diluted 30% H2O2) And after color development, measuring the absorbance at 450nm and 630nm by using an enzyme-labeling instrument, drawing a histogram, and comparing the steps to obtain the binding performance of the phage antibody with the S protein and the BSA.
The results of the enzyme-linked immunosorbent assay are shown in fig. 1, and when the binding capacities of the phage libraries R0, R2 and R3 obtained in the phage panning process and the S protein are compared, it is found that the binding capacity of the phage solution R2 obtained in the second panning process and the S protein is significantly increased, and the binding performance to BSA is very weak and unchanged, which indicates that the antibodies against the new coronavirus S protein in the constructed phage display antibody library are enriched.
Thirdly, screening of monoclonal antibody
Culturing TG-1 E.coli to OD600Taking 100 mu L of elutriation sieve R2 phage antibody library dissolved out phage solution for infecting 200 mu L of escherichia coli bacterial solution, incubating for 30 minutes at 37 ℃, coating the bacterial solution on a 2YT culture medium plate containing 100 mu g/mL ampicillin, 50 mu g/mL kanamycin and 1% glucose, and culturing overnight at 37 ℃; the next day, 96 colonies were picked and inoculated onto 96-well plates, and cultured at 37 ℃ to OD600To 0.4, M13 phage was added to each well, centrifuged at 5000g for 20 minutes after infection, the supernatant was removed, 200. mu.L of 2YT medium containing 100. mu.g/mL ampicillin, 50. mu.g/mL kanamycin and 0.1% glucose was added to each well, the cells were suspended, and cultured at 30 ℃ and 250rpm for 16 hours; centrifuging the culture solution at 5000g for 30 min the next day, separating and recovering supernatant, performing enzyme-linked immunosorbent assay, and verifying each single gramBinding specificity and binding Performance of the monoclonal antibody to the S protein.
The enzyme-linked immunosorbent assay was performed as follows: 100 μ L of PBS solution containing virus S protein (1 μ g/mL) was added to a 96-well plate, overnight at 4 ℃, the antigen solution was discarded the next day, 200 μ L of a solution containing 2% skim milk powder was added, incubation was performed at 25 ℃ for 2 hours, and the plate was blocked. Washing the ELISA plate with PBS solution containing 0.1% Tween 20 for 3 times, adding phage solution, incubating at 25 deg.C for 1 hr, washing the ELISA plate with PBST solution, adding HRP-labeled mouse anti-M13 antibody, incubating for 1 hr, washing the plate with PBST, adding HRP substrate TMBZ (prepared with sodium acetate solution of pH6.0, containing 1/10000 diluted 30% H)2O2) After the development, absorbance at 450nm was measured with a microplate reader, a histogram was drawn, and the binding properties of the phage antibody prepared by each clone to S protein and bovine serum albumin were compared.
According to the experimental results, 6 microwells are dark in color, the absorbance of the microwells is 1.40, 1.30, 1.35, 1.05, 1.10 and 0.80 respectively, after the thallus corresponding to the microwells is subjected to amplification culture, plasmids are extracted from the antibodies in the microwells with the absorbance of 1.1 and subjected to gene sequencing, the antibodies are named as monoclonal antibodies C3 according to the positions (C rows and 3 columns) of the microwells in the experiment, the plasmids are extracted from the antibodies in the microwells with the absorbance of 1.3 and subjected to gene sequencing, the antibodies are named as monoclonal antibodies A3 according to the positions (A rows and 3 columns) of the microwells in the experiment, and the antibodies are compared with the antibody sequences registered in an antibody gene library, so that the antibodies are novel antibodies, and the same sequences as the antibody genes are not found. The details of the amino acid sequence of the antibody are as follows.
The heavy chain variable region sequence of the C3 antibody is SEQ ID NO: 1, CDRH1 sequence of SEQ ID NO: 2; the CDRH2 sequence is SEQ ID NO: 3; the CDRH3 sequence is SEQ ID NO: 4;
the variable region sequence of the light chain of the C3 antibody is SEQ ID NO: 5, CDRL1 sequence is SEQ ID NO: 6; the CDRL2 sequence is SEQ ID NO: 7; the CDRL3 sequence is SEQ ID NO: 8.
the heavy chain variable region sequence of the A3 antibody is SEQ ID NO: 9, CDRH1 sequence as SEQ ID NO: 10; the CDRH2 sequence is SEQ ID NO: 11; the CDRH3 sequence is SEQ ID NO: 12;
the variable region sequence of the light chain of the A3 antibody is SEQ ID NO: 13, CDRL1 sequence of SEQ ID NO: 14; the CDRL2 sequence is SEQ ID NO: 15; the CDRL3 sequence is SEQ ID NO: 16.
the sequence referred to by C3 has the following specific information:
SEQ ID NO:1:
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSSIASSGYYTDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDADSFDYWGQGTLVTVSS;
SEQ ID NO:2:GFTFSSYA;
SEQ ID NO:3:IASSGYYT;
SEQ ID NO:4:AKDADSFDY;
SEQ ID NO:5:
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASYLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAYSAPSTFGQGTKVEIKR;
SEQ ID NO:6:QSISSY;
SEQ ID NO:7:AAS;
SEQ ID NO:8:QQAYSAPST;
the sequence referred to by A3 has the following specific information:
SEQ ID NO:9:
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSYITDDGANTSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSYATFDYWGQGTLVTVSS;
SEQ ID NO:10:
GFTFSSYA;
SEQ ID NO:11:
ITDDGANT;
SEQ ID NO:12:
AKSYATFDY;
SEQ ID NO:13:
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYNASGLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAAYYPTTFGQGTKVEIKR;
SEQ ID NO:14:
QSISSY;
SEQ ID NO:15:
NAS;
SEQ ID NO:16:
QQAAYYPTT。
fourth, antigen specificity of monoclonal antibody
Adding 100 mu L of new coronavirus S protein, S-RBD protein and BSA protein solution with the concentration of 1 mu g/mL into a 96-hole enzyme label plate, staying overnight at 4 ℃, discarding the protein solution the next day, adding 200 mu L of 2% skimmed milk powder solution, incubating for 2 hours at 25 ℃, and sealing the enzyme label plate; after washing the microplate 3 times with PBS containing 0.1% Tween 20, 100. mu.L of diluted phage display antibody solution was added to each well, incubated at 25 ℃ for 1 hour, the microplate was washed with PBST solution, HRP-labeled mouse anti-M13 antibody was added, and after incubation for 1 hour, the microplate was washed with PBST, and HRP substrate TMBZ (prepared with sodium acetate solution pH6.0, containing 1/10000 diluted 30% H) was added2O2) After the development, absorbance at 450nm was measured with a microplate reader, a histogram was plotted, and the binding properties of the phage antibody produced by each clone and the envelope protein were compared.
The results of ELISA using monoclonal antibody C3 are shown in FIG. 2, in which C3 binds to S protein and S-RBD protein, and C3 antibody was compared with coated BSA as an antibody recognizing RBD region of S protein, indicating that the binding of C3 antibody to S protein is specific.
The results of ELISA using monoclonal antibody A3 are shown in FIG. 3, in which A3 binds to S protein, but binds to S-RBD protein only weakly and mainly to the region other than the RBD region of S protein, and A3 antibody shows specificity in binding to S protein when compared to coated BSA.
Fifthly, detecting the novel coronavirus S protein by using the Fab fragment of the C3 antibody and the A3 antibody displayed by phage
The detection principle is shown in FIG. 4, the C3 protein and A3 displayed by phage are used for detecting the S protein of the new coronavirus, the Fab fragment of the C3 antibody is coated in the hole of a 96-hole microplate, the microplate is sealed, S protein or BSA protein is added, phage display A3 antibody is added after the plate is washed, then anti-phage antibody which is marked with horse radish peroxidase is added, the plate is washed, and then substrate is added for color development, when the sample does not contain new coronavirus S protein or BSA protein, the reaction system does not develop color, when virus S protein exists, the system develops color, and the more virus S protein in the sample, the more A3 phage captured to the microplate by the virus S protein, the more anti-phage antibody captured correspondingly, and the darker the color of the enzyme-added substrate after development, and the method can be used to determine whether there is virus S1 protein in the sample, the method can also be used to detect the presence of SARS-CoV-2 virus in a sample.
The specific operation is as follows: adding the Fab fragment of the C3 antibody into the hole of the 96-hole enzyme label plate, staying overnight at 4 ℃, discarding the liquid in the hole the next time, adding 200 mu L of 2% skimmed milk powder solution, standing for two hours at room temperature, and sealing the enzyme label plate. After washing the plate, 100. mu.L of a solution containing the S protein of the novel coronavirus or a Bovine Serum Albumin (BSA) solution was added to the wells, incubated at 25 ℃ for 1 hour, the well-containing solution was removed, the plate was washed with a PBS solution (PBST solution) containing 0.1% Tween, and a phage-displayed A3 antibody solution (10) was added9cfu/mL), incubation for 1 hour at 25 ℃, adding an anti-phage antibody solution (1 mu g/mL) marked with horseradish peroxidase (HRP) after plate washing, incubation for 1 hour at 25 ℃, removing the solution in the wells, washing the plates for 3 times by PBST, finally adding an HRP substrate 3,3,5, 5-tetramethylbenzidine hydrochloride (TMBZ) solution for color development, measuring the absorbance of the solution in the wells at 450nm and 630nm, making a histogram, and comparing the binding capacity of the antibody with the S protein of the new coronavirus and the bovine serum albumin.
As shown in FIG. 5, the C3 antibody combined with phage-displayed A3 detected viral S protein, with the horizontal axis representing the name of the detected protein and the vertical axis representing the absorbance of the solution in the corresponding well. The absorbance of the wells containing the viral S protein ELISA in the solution of the combination of C3 and A3 was 0.64, while the absorbance of the wells with BSA added was 0.02, indicating that the combination with A3 can be used to detect the novel coronavirus S protein in solution.
Sequence listing
<110> Weifang medical college
<120> monoclonal antibody aiming at new coronavirus SARS-CoV-2 spinous process protein RBD region and application thereof
<141> 2020-09-04
<150> 2020104148681
<151> 2020-05-15
<160> 16
<170> SIPOSequenceListing 1.0
<210> 1
<211> 116
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 1
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Ala Ser Ser Gly Tyr Tyr Thr Asp Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Asp Ala Asp Ser Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110
Thr Val Ser Ser
115
<210> 2
<211> 8
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 2
Gly Phe Thr Phe Ser Ser Tyr Ala
1 5
<210> 3
<211> 8
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 3
Ile Ala Ser Ser Gly Tyr Tyr Thr
1 5
<210> 4
<211> 9
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 4
Ala Lys Asp Ala Asp Ser Phe Asp Tyr
1 5
<210> 5
<211> 108
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 5
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Tyr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Tyr Ser Ala Pro Ser
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105
<210> 6
<211> 6
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 6
Gln Ser Ile Ser Ser Tyr
1 5
<210> 7
<211> 3
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 7
Ala Ala Ser
1
<210> 8
<211> 9
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 8
Gln Gln Ala Tyr Ser Ala Pro Ser Thr
1 5
<210> 9
<211> 116
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 9
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Tyr Ile Thr Asp Asp Gly Ala Asn Thr Ser Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Lys Ser Tyr Ala Thr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110
Thr Val Ser Ser
115
<210> 10
<211> 8
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 10
Gly Phe Thr Phe Ser Ser Tyr Ala
1 5
<210> 11
<211> 8
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 11
Ile Thr Asp Asp Gly Ala Asn Thr
1 5
<210> 12
<211> 9
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 12
Ala Lys Ser Tyr Ala Thr Phe Asp Tyr
1 5
<210> 13
<211> 108
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 13
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Asn Ala Ser Gly Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Ala Tyr Tyr Pro Thr
85 90 95
Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105
<210> 14
<211> 6
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 14
Gln Ser Ile Ser Ser Tyr
1 5
<210> 15
<211> 3
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 15
Asn Ala Ser
1
<210> 16
<211> 9
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 16
Gln Gln Ala Ala Tyr Tyr Pro Thr Thr
1 5

Claims (9)

1. A monoclonal antibody against the RBD region of the spike protein of the novel coronavirus SARS-CoV-2, which is characterized in that: the monoclonal antibody is specifically combined with an RBD region of spinous process glycoprotein of a novel coronavirus SARS-CoV-2, and comprises complementarity determining regions CDRH1, CDRH2 and CDRH3 of a heavy chain variable region and complementarity determining regions CDRL1, CDRL2 and CDRL3 of a light chain variable region; the amino acid sequences of the complementarity determining regions CDRH1, CDRH2 and CDRH3 of the heavy chain variable region are SEQ ID NO: 2. SEQ ID NO: 3 and SEQ ID NO: 4; the amino acid sequences of the complementarity determining regions CDRL1, CDRL2 and CDRL3 of the light chain variable region are SEQ ID NO: 6. SEQ ID NO: 7 and SEQ ID NO: 8.
2. the monoclonal antibody against the RBD region of the spike protein of the novel coronavirus SARS-CoV-2 according to claim 1, wherein: the amino acid sequence of the heavy chain variable region of the monoclonal antibody is SEQ ID NO: 1, the amino acid sequence of the light chain variable region of the monoclonal antibody is SEQ ID NO: 5.
3. an isolated nucleic acid molecule, wherein: the nucleic acid molecule encodes the monoclonal antibody of any one of claims 1-2.
4. An expression vector comprising the nucleic acid molecule of claim 3.
5. A host cell comprising the nucleic acid molecule of claim 3 or the expression vector of claim 4.
6. A method for detecting the level of the novel coronavirus SARS-CoV-2 for non-diagnostic purposes, comprising: the method comprises the following steps:
extracting a sample containing new coronavirus SARS-CoV-2;
contacting the sample obtained in the step I with the monoclonal antibody of any one of claims 1-2;
and thirdly, detecting the immunoreaction of the sample and the monoclonal antibody.
7. The use of the monoclonal antibody against the spinous process protein RBD region of the novel coronavirus SARS-CoV-2 as claimed in any one of claims 1-2 in the preparation of a novel coronavirus SARS-CoV-2 detection product.
8. The use of the monoclonal antibody against the spinous process protein RBD region of the neocoronavirus SARS-CoV-2 as claimed in any one of claims 1-2 in the preparation of a medicament for inhibiting the neocoronavirus SARS-CoV-2.
9. The use of the monoclonal antibody against the spinous process protein RBD region of the neocoronavirus SARS-CoV-2 as claimed in any one of claims 1 to 2 in the preparation of an antibody pharmaceutical preparation for preventing or treating pneumonia caused by the neocoronavirus SARS-CoV-2.
CN202010922039.4A 2020-05-15 2020-09-04 Monoclonal antibody aiming at new coronavirus SARS-CoV-2 spinous process protein RBD region and application thereof Active CN111995675B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020104148681 2020-05-15
CN202010414868 2020-05-15

Publications (2)

Publication Number Publication Date
CN111995675A true CN111995675A (en) 2020-11-27
CN111995675B CN111995675B (en) 2021-03-23

Family

ID=73392174

Family Applications (7)

Application Number Title Priority Date Filing Date
CN202010926558.8A Active CN112010966B (en) 2020-05-15 2020-09-04 Monoclonal antibody aiming at non-RBD (radial basis function) region of new coronavirus spike protein and application thereof
CN202010926533.8A Active CN112010965B (en) 2020-05-15 2020-09-04 Monoclonal antibody aiming at new coronavirus SARS-CoV-2 spinous process protein RBD region and application thereof
CN202010922039.4A Active CN111995675B (en) 2020-05-15 2020-09-04 Monoclonal antibody aiming at new coronavirus SARS-CoV-2 spinous process protein RBD region and application thereof
CN202010921453.3A Active CN111961133B (en) 2020-05-15 2020-09-04 Monoclonal antibody aiming at novel coronavirus SARS-CoV-2 spinous process protein non-RBD region and application thereof
CN202010926531.9A Active CN111995676B (en) 2020-05-15 2020-09-04 Monoclonal antibody aiming at non-RBD (radial basis function) region of new coronavirus spike protein and application thereof
CN202010944546.8A Active CN111995677B (en) 2020-05-15 2020-09-10 Monoclonal antibody aiming at non-RBD (radial basis function) region of new coronavirus spike protein and application thereof
CN202010944547.2A Active CN111995678B (en) 2020-05-15 2020-09-10 Monoclonal antibody aiming at new coronavirus SARS-CoV-2 spinous process protein RBD region and application thereof

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN202010926558.8A Active CN112010966B (en) 2020-05-15 2020-09-04 Monoclonal antibody aiming at non-RBD (radial basis function) region of new coronavirus spike protein and application thereof
CN202010926533.8A Active CN112010965B (en) 2020-05-15 2020-09-04 Monoclonal antibody aiming at new coronavirus SARS-CoV-2 spinous process protein RBD region and application thereof

Family Applications After (4)

Application Number Title Priority Date Filing Date
CN202010921453.3A Active CN111961133B (en) 2020-05-15 2020-09-04 Monoclonal antibody aiming at novel coronavirus SARS-CoV-2 spinous process protein non-RBD region and application thereof
CN202010926531.9A Active CN111995676B (en) 2020-05-15 2020-09-04 Monoclonal antibody aiming at non-RBD (radial basis function) region of new coronavirus spike protein and application thereof
CN202010944546.8A Active CN111995677B (en) 2020-05-15 2020-09-10 Monoclonal antibody aiming at non-RBD (radial basis function) region of new coronavirus spike protein and application thereof
CN202010944547.2A Active CN111995678B (en) 2020-05-15 2020-09-10 Monoclonal antibody aiming at new coronavirus SARS-CoV-2 spinous process protein RBD region and application thereof

Country Status (1)

Country Link
CN (7) CN112010966B (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112611868A (en) * 2020-12-18 2021-04-06 厦门大学 Probe for detecting novel coronavirus by magnetic resonance analysis method and preparation method thereof
CN112940110A (en) * 2021-04-14 2021-06-11 中山大学 Anti-novel coronavirus N protein monoclonal antibody and application thereof
CN113307866A (en) * 2021-05-26 2021-08-27 中山大学 Antibody composition and application thereof
CN113416245A (en) * 2021-06-15 2021-09-21 北京华大蛋白质研发中心有限公司 Neutralizing antibody capable of combining SARS-CoV-2 virus RBD protein and application thereof
CN113999301A (en) * 2021-12-07 2022-02-01 江苏中新医药有限公司 anti-SARS-CoV-2 (COVID-19) S protein RBD monoclonal antibody
WO2022068847A1 (en) * 2020-09-29 2022-04-07 山东博安生物技术股份有限公司 Method for treating or preventing diseases caused by novel coronavirus sars-cov-2
CN114573690A (en) * 2020-12-02 2022-06-03 深圳先进技术研究院 anti-SAR-COV-2 fully human monoclonal antibody and preparation method and application thereof
WO2022161491A1 (en) * 2021-01-29 2022-08-04 中国科学院上海巴斯德研究所 Neutralizing antibody for sars-cov-2 virus
CN115141270A (en) * 2021-03-29 2022-10-04 深圳市康麦生物技术有限公司 Antibodies that specifically bind to novel coronaviruses
WO2023125964A1 (en) * 2022-01-03 2023-07-06 Versitech Limited Neutralizing antibodies against covid-19 and methods of use thereof
US11820811B2 (en) 2020-09-22 2023-11-21 Shihezi University Nano-antibody and its application based on SARS-CoV-2 S protein
WO2024125667A1 (en) * 2022-12-12 2024-06-20 首都医科大学 Monoclonal antibody against sars-cov or sars-cov-2, preparation method therefor and use thereof

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020340881A1 (en) 2020-04-02 2021-10-21 Regeneron Pharmaceuticals, Inc. Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
CN116057069A (en) 2020-06-03 2023-05-02 瑞泽恩制药公司 Methods of treating or preventing SARS-CoV-2 infection and COVID-19 using anti-SARS-CoV-2 spike glycoprotein antibodies
CN118085068A (en) * 2020-08-19 2024-05-28 重庆医科大学 New coronavirus RBD specific monoclonal antibody and application
CN114989293B (en) * 2020-08-19 2023-10-17 重庆医科大学 New coronavirus RBD specific monoclonal antibody and application
CN112409479B (en) * 2020-11-23 2022-04-26 中国疾病预防控制中心病毒病预防控制所 Humanized anti-neocoronavirus neutralizing antibody nCoV-121 and application thereof
CN112574300B (en) * 2020-12-02 2022-03-08 深圳先进技术研究院 anti-SAR-COV-2 fully human monoclonal antibody and preparation method and application thereof
CN114605527B (en) * 2020-12-04 2023-07-04 中国科学院分子细胞科学卓越创新中心 Antibody for resisting novel coronavirus SARS-CoV-2 and its preparation method and use
CN114685653B (en) * 2020-12-31 2023-09-12 中国科学院分子细胞科学卓越创新中心 Neutralizing antibodies against epitopes of novel coronavirus receptor binding region and uses thereof
US11834493B2 (en) * 2021-01-05 2023-12-05 Immunome, Inc. Antibody cocktail against SARS-CoV-2 spike protein
CN114716541B (en) * 2021-01-05 2023-07-21 中国科学院分子细胞科学卓越创新中心 Fully human broad spectrum neutralizing antibody 76E1 against coronavirus and application thereof
CN112394180A (en) * 2021-01-19 2021-02-23 南京立顶医疗科技有限公司 Detection method and detection kit for SARS-CoV-2 neutralizing antibody
CN113150129B (en) * 2021-01-28 2023-02-28 四川大学华西医院 Single-chain antibody for resisting S2 protein on surface of new coronavirus SARS-CoV-2 and application thereof
CN112521496B (en) * 2021-01-29 2022-09-06 中国人民解放军空军军医大学 Monoclonal antibody specifically binding SARS-CoV-2 Spike RBD and application thereof
CN115109150B (en) * 2021-01-31 2024-06-25 中南大学湘雅医院 Novel coronavirus monoclonal antibody XY10 and application thereof
CN115427432A (en) * 2021-02-10 2022-12-02 斯微(上海)生物科技股份有限公司 Vaccine agent for treating or preventing coronavirus disease mutant strain
CN113009154B (en) * 2021-02-25 2024-01-30 山东莱博生物科技有限公司 Novel one-step method coronavirus neutralizing antibody magnetic microsphere detection kit and application thereof
CN113150135B (en) * 2021-04-14 2022-09-20 中山大学 Neutralizing antibodies against novel coronavirus receptor binding domains and uses thereof
WO2022241415A1 (en) * 2021-05-11 2022-11-17 Yale University Methods for monoclonal antibody generation
WO2022241200A1 (en) * 2021-05-14 2022-11-17 Vanderbilt University Cross-reactive coronavirus antibodies
CN113402603B (en) * 2021-06-09 2022-05-03 陕西理工大学 Avian single-chain antibody for resisting SARS-CoV-2 virus S1 protein and its application
CN113501872B (en) * 2021-06-22 2022-05-24 中国医学科学院病原生物学研究所 Human source anti-novel coronavirus SARS-CoV-2 neutralizing antibody SK1 and application thereof
CN113563483B (en) * 2021-08-09 2024-02-02 广州明药科技有限公司 Phage display novel coronavirus capsid protein and application
CN113603786B (en) * 2021-08-26 2023-05-30 深圳市亚辉龙生物科技股份有限公司 Bispecific antibodies that specifically bind SARS-CoV-2S protein and N protein
CN113929772B (en) * 2021-09-30 2022-03-25 北京康乐卫士生物技术股份有限公司 SARS-CoV-2 neutralizing antibody and its preparation method and use
CN114133447B (en) * 2021-10-14 2022-07-19 河南晟明生物技术研究院有限公司 Preparation method and application of 2019-nCoV surface protein receptor binding region antibody
CN118434762A (en) * 2021-10-26 2024-08-02 豪夫迈·罗氏有限公司 Monoclonal antibodies specific for SARS-CoV-2 RBD
CN114989291B (en) * 2021-11-25 2023-01-06 浙江安维珞诊断技术有限公司 RBD-targeted anti-SARS-CoV-2 fully humanized monoclonal antibody and application thereof
CN116925177A (en) * 2021-12-06 2023-10-24 浙江大学 Novel affinity polypeptide of coronavirus spike protein receptor binding region RBD and application thereof
CN114106164B (en) * 2021-12-09 2023-05-26 杭州旭科生物技术有限公司 Monoclonal antibody for resisting novel coronavirus S protein and application thereof
CN114702578B (en) * 2022-06-06 2022-09-27 百斯医学诊断科技(北京)有限公司 Novel coronavirus Omicron mutant strain specific antibody and application thereof
CN115894675B (en) * 2023-02-03 2023-11-14 康复大学(筹) New coronavirus SARS-CoV-2 nucleocapsid protein monoclonal antibody and its application
CN117551191A (en) * 2023-11-15 2024-02-13 江苏省疾病预防控制中心(江苏省公共卫生研究院) Monoclonal antibodies against SARS-CoV-2

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1648927A1 (en) * 2003-07-21 2006-04-26 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Soluble fragments of the sars-cov spike glycoprotein
MX2007009512A (en) * 2005-02-08 2008-02-21 New York Blood Ct Inc Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus.
WO2009128963A2 (en) * 2008-01-17 2009-10-22 Humab, Llc Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
CN111157723B (en) * 2020-02-16 2023-07-04 广西中医药大学附属瑞康医院 Novel coronavirus rapid detection box
CN110951756B (en) * 2020-02-23 2020-08-04 广州恩宝生物医药科技有限公司 Nucleic acid sequence for expressing SARS-CoV-2 virus antigen peptide and its application
CN111592594B (en) * 2020-03-13 2022-05-10 北京大学 Monoclonal antibody for resisting novel coronavirus and application thereof
CN111122879B (en) * 2020-03-26 2020-07-14 珠海丽珠试剂股份有限公司 Coating liquid of novel coronavirus recombinant antigen, pretreatment method, application and product
CN111690059B (en) * 2020-06-19 2022-03-08 武汉生物制品研究所有限责任公司 Monoclonal antibody 1D7 for resisting SARS-CoV-2
CN111995672B (en) * 2020-07-20 2022-05-20 江苏集萃医学免疫技术研究所有限公司 Specific antibody of coronavirus SARS-COV-2S protein and its use
CN111925440B (en) * 2020-08-19 2022-09-09 重庆医科大学 New coronavirus RBD specific monoclonal antibody and application

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11820811B2 (en) 2020-09-22 2023-11-21 Shihezi University Nano-antibody and its application based on SARS-CoV-2 S protein
WO2022068847A1 (en) * 2020-09-29 2022-04-07 山东博安生物技术股份有限公司 Method for treating or preventing diseases caused by novel coronavirus sars-cov-2
CN114573690A (en) * 2020-12-02 2022-06-03 深圳先进技术研究院 anti-SAR-COV-2 fully human monoclonal antibody and preparation method and application thereof
CN114573690B (en) * 2020-12-02 2023-12-12 深圳先进技术研究院 anti-SAR-COV-2 fully human monoclonal antibody and preparation method and application thereof
CN112611868A (en) * 2020-12-18 2021-04-06 厦门大学 Probe for detecting novel coronavirus by magnetic resonance analysis method and preparation method thereof
WO2022161491A1 (en) * 2021-01-29 2022-08-04 中国科学院上海巴斯德研究所 Neutralizing antibody for sars-cov-2 virus
CN115141270A (en) * 2021-03-29 2022-10-04 深圳市康麦生物技术有限公司 Antibodies that specifically bind to novel coronaviruses
CN112940110B (en) * 2021-04-14 2022-09-20 中山大学 Anti-novel coronavirus N protein monoclonal antibody and application thereof
CN112940110A (en) * 2021-04-14 2021-06-11 中山大学 Anti-novel coronavirus N protein monoclonal antibody and application thereof
CN113307866A (en) * 2021-05-26 2021-08-27 中山大学 Antibody composition and application thereof
CN113416245A (en) * 2021-06-15 2021-09-21 北京华大蛋白质研发中心有限公司 Neutralizing antibody capable of combining SARS-CoV-2 virus RBD protein and application thereof
CN113999301A (en) * 2021-12-07 2022-02-01 江苏中新医药有限公司 anti-SARS-CoV-2 (COVID-19) S protein RBD monoclonal antibody
CN113999301B (en) * 2021-12-07 2023-07-28 江苏中新医药有限公司 anti-SARS-CoV-2 (COVID-19) S protein RBD monoclonal antibody
WO2023125964A1 (en) * 2022-01-03 2023-07-06 Versitech Limited Neutralizing antibodies against covid-19 and methods of use thereof
WO2024125667A1 (en) * 2022-12-12 2024-06-20 首都医科大学 Monoclonal antibody against sars-cov or sars-cov-2, preparation method therefor and use thereof

Also Published As

Publication number Publication date
CN111961133A (en) 2020-11-20
CN111995677A (en) 2020-11-27
CN112010965B (en) 2021-03-12
CN112010966B (en) 2021-03-19
CN111995678A (en) 2020-11-27
CN112010965A (en) 2020-12-01
CN111961133B (en) 2021-03-23
CN111995677B (en) 2021-03-23
CN111995676A (en) 2020-11-27
CN111995678B (en) 2021-03-09
CN111995675B (en) 2021-03-23
CN111995676B (en) 2021-03-09
CN112010966A (en) 2020-12-01

Similar Documents

Publication Publication Date Title
CN111995675B (en) Monoclonal antibody aiming at new coronavirus SARS-CoV-2 spinous process protein RBD region and application thereof
CN111778218B (en) Phage display antibody library and monoclonal antibody aiming at novel coronavirus SARS-CoV-2 obtained based on panning of phage display antibody library
CN111647076B (en) Neutralizing single-domain antibody for resisting novel coronavirus SARS-Cov-2 and application thereof
US11661448B2 (en) Nano-antibody and its application based on SARS-CoV-2 S protein S1 subunit
US11820811B2 (en) Nano-antibody and its application based on SARS-CoV-2 S protein
CN113150129B (en) Single-chain antibody for resisting S2 protein on surface of new coronavirus SARS-CoV-2 and application thereof
CN112062838B (en) Neutralizing single-domain antibody for resisting novel coronavirus SARS-Cov-2 and application thereof
WO2022061594A1 (en) Sars-cov-2 spike protein binding molecule and use thereof
WO2023125520A1 (en) CAMEL-DERIVED NANOBODY WITH HIGH-AFFINITY FOR α, β, γ AND δ MUTANT STRAINS OF SARS-COV-2
WO2023216623A1 (en) CAMEL-DERIVED HIGH-AFFINITY NANOANTIBODY AGAINST SARS-COV-2 α, γ, δ AND ο MUTANTS
CN106188283B (en) Nano antibody of avian influenza A H7N2 and application thereof
CN113861288A (en) Novel coronavirus SARS-CoV-2 broad spectrum neutralizing antibody and its use
CN114478755B (en) Fully human antibody against novel coronavirus, composition and application thereof
CN114773459B (en) Nano antibody for resisting novel coronavirus and variant thereof, preparation method and application thereof
CN114539395B (en) SARS-CoV-2 wild strain and alpha mutant strain camel-derived high affinity nanobody
CN107513099A (en) A kind of polystyrene affinity peptide and its method for improving antigen fixed effect
CN110845607B (en) H1N1 influenza virus antibody and application thereof in H1N1 virus ultramicro-detection
CN114316009B (en) Protein capable of combining multiple viruses and application thereof
CN113943367B (en) Single domain antibodies against novel coronaviruses, kits and medicaments
CN117659183A (en) anti-H5 subtype avian influenza nanobody protein and application thereof
CN117069830A (en) Nanometer antibody for novel coronavirus and application thereof
CN117164705A (en) Nanometer antibody of H5 subtype avian influenza virus hemagglutinin protein

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant